Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease

Author(s): Laura Xicota, Jose Rodriguez-Morato, Mara Dierssen, Rafael de la Torre

Journal Name: Current Drug Targets

Volume 18 , Issue 2 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Medical advances in the last decades have increased the average life expectancy, but also the incidence and prevalence of age-associated neurodegenerative diseases. Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases and the most prevalent type of dementia. A plethora of different mechanisms contribute to AD, among which oxidative stress plays a key role in its development and progression. So far, there are no pharmacological treatments available and the current medications are mainly symptomatic. In the last years, dietary polyphenols have gained research attention due to their interesting biological activities, and more specifically their antioxidant properties. (-)- Epigallocatechin-3-gallate (EGCG) is a natural flavanol that has been extensively studied regarding its potential effects in AD. In this review we present the current in vitro and in vivo experimentation regarding the use of EGCG in AD. We also review the complex mechanisms of action of EGCG, not only limited to its antioxidant activity, which may explain its beneficial health effects.

Keywords: Alzheimer disease, (-)-epigallocatechin-3-gallate, green tea, neurodegenerative diseases, neuroprotection, oxidative stress.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 28 December, 2016
Page: [174 - 195]
Pages: 22
DOI: 10.2174/1389450116666150825113655
Price: $65

Article Metrics

PDF: 61